We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration with O2h
News

Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration with O2h

Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration with O2h
News

Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration with O2h

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Heptares Therapeutics Extends Multi-FTE Chemistry Collaboration with O2h"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Executives from Heptares Therapeutics and Oxygen Healthcare (O2h) announced an extension of the agreement under which O2h provides multi-FTE -synthetic chemistry services to support discovery programmes at Heptares.

Dr. Miles Congreve, Head of Chemistry said, “We are happy to have signed this new contract with O2h; they have been a solid chemistry partner and have also supported us with some basic ADME, which helps to reduce discovery cycle times.”

Sunil Shah, CEO, O2h “We have had a successful partnership with Heptares Therapeutics and are delighted at this extension for the third year. Heptares has a very innovative technology that we are happy to have supported since inception and believe will lead to new GPCR drugs being discovered.”
Advertisement